Articles Tập 67 Số CĐ14-HNKH Hội Hóa sinh Y học Việt Nam 19/09/2026

PREVALENCE OF MASLD AND COEXISTING METABOLIC DISORDERS AMONG INDIVIDUALS UNDERGOING ROUTINE HEALTH CHECK-UP AT UNIVERSITY MEDICAL CENTER HO CHI MINH CITY

Nguyen Duy Dat, Van Hy Triet, Nguyen Truong Cong Minh, Nguyen Thi Thuy Lieu, Tong Nguyen Thanh Cong, Mai Thuy Giang, Nguyen Thi Le Huong
DOI: 10.52163/yhc.v67iCD14.6473
0 Views
0 Downloads
Abstract

Objective: To evaluate the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and the burden of coexisting metabolic disorders among individuals undergoing routine health check-ups in Vietnam.

Methods: A cross-sectional descriptive study was conducted on 1,339 subjects undergoing periodic health check-ups at the University of Medicine and Pharmacy Hospital, Ho Chi Minh City, from December 2025 to March 2026. MASLD was diagnosed according to the current diagnostic criteria. Anthropometric indices, medical history, and laboratory test results were collected and analyzed according to MASLD status.

Results: The prevalence rate of MASLD was 39.88% (534/1,339). The MASLD group had a significantly higher proportion of males (49.63% vs 19.13%, p<0.001), higher BMI, and larger waist circumference. Among patients with MASLD, the rates of coexisting metabolic disorders were very high: dyslipidemia 89.33%, overweight/obesity 82.02%, dysglycemia 72.47%, and hypertension 33.15%. Notably, 68.17% of MASLD patients had three or more coexisting metabolic disorders.

Conclusion: MASLD is highly prevalent among individuals undergoing routine health check-ups and is strongly associated with a substantial burden of multiple metabolic disorders. These findings highlight the need for systematic screening and early intervention targeting metabolic risk factors to reduce the long-term burden of MASLD.

Keywords
MASLD, steatotic liver disease, metabolic disorders, metabolic syndrome, routine health check-up.
References
[1]
1. Pham AG, Le AV-K, Pham YT-H, Nguyen LS, Nguyen HL, Quach NC, et al. Predictors of metabolic dysfunction-associated steatotic liver diseases (MASLD) in Vietnamese population. Scientific Reports. 2026;16(1):17802. Google Scholar
[2]
2. Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31(Suppl):S32-s50. Google Scholar
[3]
3. Vũ Quốc B, Trần Thị Khánh T, Huỳnh Tiểu N. Tỷ lệ chẩn đoán bệnh gan nhiễm mỡ và xơ hóa gan theo thuật ngữ NAFLD, MAFLD, MASLD ở bệnh nhân đái tháo đường típ 2. Tạp chí Khoa học Tiêu hóa Việt Nam. 2025;13(78). Google Scholar
[4]
4. Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, Bannuru RR, Barb D, et al. Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025;48(7):1057-82. Google Scholar
[5]
5. Zheng H, Sechi LA, Navarese EP, Casu G, Vidili G. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. Cardiovascular Diabetology. 2024;23(1):346. Google Scholar
[6]
6. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology. 2020;73(1):202-9. Google Scholar
[7]
7. Lu NL, Lam HT, Vo TD. Prevalence of metabolic dysfunction-associated fatty liver disease among health check-up attendees: A retrospective study conducted in Vietnam. World J Gastroenterol. 2025;31(37):110797. Google Scholar
[8]
8. Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P, et al. Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals. The Journal of Clinical Endocrinology & Metabolism. 2022;107(9):2691-700. Google Scholar
[9]
9. Ho GJK, Tan FXN, Sasikumar NA, Tham EKJ, Ko D, Kim DH, et al. High Global Prevalence of Steatotic Liver Disease and Associated Subtypes: A Meta-analysis. Clinical Gastroenterology and Hepatology. 2025;23(13):2423-32.e1. Google Scholar
[10]
10. Gutierrez-Grobe Y, Ponciano-Rodríguez G, Ramos MH, Uribe M, Méndez-Sánchez N. Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol. 2010;9(4):402-9. Google Scholar
[11]
11. Chen YL, Li H, Li S, Xu Z, Tian S, Wu J, et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. BMC Gastroenterol. 2021;21(1):212. Google Scholar